Immune checkpoint modulators in early clinical development for the treatment of type 1 diabetes

IF 4.9 2区医学 Q1 PHARMACOLOGY & PHARMACY

Expert opinion on investigational drugs Pub Date : 2024-03-01 DOI:10.1080/13543784.2024.2326036

Ernesto Maddaloni, Rocco Amendolara, Angela Balena, Alessandro Latino, Rosario Luigi Sessa, Raffaella Buzzetti

引用次数: 0

Abstract

. Despite the improvements of insulin therapy, people with type 1 diabetes (T1D) still suffer from a decreased quality of life and life expectancy. The search toward a cure for T1D is therefore sti...

查看原文本刊更多论文

用于治疗 1 型糖尿病的早期临床开发免疫检查点调节剂

.尽管胰岛素疗法有所改善，但1型糖尿病（T1D）患者的生活质量和预期寿命仍在下降。因此，寻找治愈 T1D 的方法是一项艰巨的任务。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert opinion on investigational drugs 医学-药学

CiteScore

10.00

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Expert Opinion on Investigational Drugs (ISSN 1354-3784 [print], 1744-7658 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on drugs in preclinical and early stage clinical development, providing expert opinion on the scope for future development. The Editors welcome: Reviews covering preclinical through to Phase II data on drugs or drug classes for specific indications, and their potential impact on future treatment strategies Drug Evaluations reviewing the clinical and pharmacological data on a particular drug Original Research papers reporting the results of clinical investigations on agents that are in Phase I and II clinical trials The audience consists of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in R&D.